BioGend Therapeutics Co (ROCO:6733) EV-to-Revenue : 29.00 (As of May. 24, 2024)

View and export this data going back to 2019. Start your Free Trial

What is BioGend Therapeutics Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BioGend Therapeutics Co's enterprise value is NT$3,905.2 Mil. BioGend Therapeutics Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was NT$134.6 Mil. Therefore, BioGend Therapeutics Co's EV-to-Revenue for today is 29.00.

The historical rank and industry rank for BioGend Therapeutics Co's EV-to-Revenue or its related term are showing as below:

ROCO:6733' s EV-to-Revenue Range Over the Past 10 Years
Min: 28.43 Med: 205.15 Max: 6777.21
Current: 29

During the past 8 years, the highest EV-to-Revenue of BioGend Therapeutics Co was 6777.21. The lowest was 28.43. And the median was 205.15.

ROCO:6733's EV-to-Revenue is ranked worse than
71.29% of 1038 companies
in the Biotechnology industry
Industry Median: 8.22 vs ROCO:6733: 29.00

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-24), BioGend Therapeutics Co's stock price is NT$36.45. BioGend Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was NT$1.12. Therefore, BioGend Therapeutics Co's PS Ratio for today is 32.49.

BioGend Therapeutics Co EV-to-Revenue Historical Data

The historical data trend for BioGend Therapeutics Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGend Therapeutics Co EV-to-Revenue Chart

BioGend Therapeutics Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

1,419.46

2,167.82

229.62

58.16

36.51

BioGend Therapeutics Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															89.85	73.29	45.65	36.51	29.71

Competitive Comparison of BioGend Therapeutics Co's EV-to-Revenue

For the Biotechnology subindustry, BioGend Therapeutics Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGend Therapeutics Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioGend Therapeutics Co's EV-to-Revenue falls into.

BioGend Therapeutics Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

BioGend Therapeutics Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	3905.197	/	134.646
	=	29.00

BioGend Therapeutics Co's current Enterprise Value is NT$3,905.2 Mil.
BioGend Therapeutics Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$134.6 Mil.

BioGend Therapeutics Co (ROCO:6733) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

BioGend Therapeutics Co's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	36.45	/	1.122
	=	32.49

BioGend Therapeutics Co's share price for today is NT$36.45.
BioGend Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.12.

BioGend Therapeutics Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioGend Therapeutics Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioGend Therapeutics Co (ROCO:6733) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioGend Therapeutics Co Ltd (ROCO:6733) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th Floor, Number 3, Park Street, Nangang District, Taipei, TWN, 115

Website

https://www.biogend.com.tw

BioGend Therapeutics Co Ltd is a Taiwan based company involved in developing regenerative bio-orthopaedic medicine to advance the clinical science of maintaining healthy joints in skeletal system. The Company is primarily engaged in the research and development of bone medical device related products. Its products under development include Big-001, Big-006 and Big-009.

BioGend Therapeutics Co (ROCO:6733) Headlines

No Headlines